Erste Group Bank Has Pessimistic View of MRK FY2026 Earnings

Merck & Co., Inc. (NYSE:MRK - Free Report) - Research analysts at Erste Group Bank dropped their FY2026 earnings estimates for shares of Merck & Co., Inc. in a research report issued on Monday, April 27th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $5.12 per share for the year, down from their previous estimate of $5.13. The consensus estimate for Merck & Co., Inc.'s current full-year earnings is $4.89 per share.

A number of other equities analysts also recently commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an "overweight" rating in a report on Monday, April 6th. Zacks Research upgraded shares of Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 17th. Guggenheim lifted their price target on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the company a "buy" rating in a report on Friday, February 6th. Wall Street Zen raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research report on Saturday, March 28th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $150.00 price objective on the stock in a research note on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $128.47.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $110.68 on Thursday. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $125.14. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $273.35 billion, a price-to-earnings ratio of 15.20, a price-to-earnings-growth ratio of 2.23 and a beta of 0.26. The business has a 50 day simple moving average of $117.94 and a 200-day simple moving average of $107.38.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.31) by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.

Hedge Funds Weigh In On Merck & Co., Inc.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Merck & Co., Inc. by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company's stock worth $26,770,014,000 after purchasing an additional 2,185,853 shares in the last quarter. State Street Corp raised its position in shares of Merck & Co., Inc. by 1.6% during the 4th quarter. State Street Corp now owns 120,040,168 shares of the company's stock worth $12,737,504,000 after buying an additional 1,859,990 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company's stock worth $9,098,196,000 after acquiring an additional 11,156,354 shares during the period. Geode Capital Management LLC lifted its stake in shares of Merck & Co., Inc. by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company's stock worth $6,307,572,000 after acquiring an additional 249,110 shares during the period. Finally, DLD Asset Management LP boosted its holdings in shares of Merck & Co., Inc. by 30.1% in the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company's stock valued at $3,986,675,000 after acquiring an additional 11,000,000 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Merck & Co., Inc.

In other news, EVP Richard R. Deluca sold 37,685 shares of the company's stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the completion of the transaction, the executive vice president owned 160,174 shares in the company, valued at approximately $19,368,240.08. This represents a 19.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the sale, the executive vice president owned 68,916 shares in the company, valued at approximately $8,211,341.40. This represents a 63.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 320,176 shares of company stock valued at $38,281,735. Company insiders own 0.17% of the company's stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck beat EPS expectations for Q1, reporting ($1.28) per share vs. consensus ($1.31) and showed strong profitability metrics (high ROE and a healthy net margin). The company published a press release and slide deck with details. View Press Release View Slide Deck
• Positive Sentiment: Sales rose ~5% with continued strong demand for Keytruda and growth from newer products; management raised its adjusted-profit outlook, which supports investor confidence in organic growth. Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
• Positive Sentiment: Guggenheim reaffirmed a Buy rating on MRK, which can provide incremental investor support. Guggenheim Reaffirms Their Buy Rating on Merck & Company (MRK)
• Neutral Sentiment: Company issued a formal Q1 financial-results release summarizing regulatory approvals and clinical milestones; useful for context but largely reiterative of earnings highlights. Business Wire Release
• Neutral Sentiment: Third‑party commentary and valuation pieces note a recent pullback and longer-term gains — these frame investor sentiment but don't change fundamentals immediately. Assessing Merck (MRK) Valuation After Recent Share Price Pullback And Long Term Gains
• Negative Sentiment: Merck posted a GAAP quarterly loss due to an acquisition-related charge tied to Cidara, which offset operational sales gains and introduces near-term earnings volatility. Merck posts quarterly loss due to Cidara charge, sales rise 5%
• Negative Sentiment: Some analysts (Erste Group) trimmed FY2026/2027 EPS forecasts slightly, reflecting caution around guidance narrowing and one‑time charges — a modest headwind for sentiment. (Analyst note reported by MarketBeat)

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.